Seeking Alpha 13 April 15 Obviously, the Celgene announcement...

Seeking Alpha 13 April 15
Obviously, the Celgene announcement was very good news for Mesoblast, and there are three obvious reasons for the share price increase.

Firstly, it provides a US vehicle (if Celgene takes up the first right of refusal on the project) for its most advanced program, JR-031 for treating acute GVHD (filed for approval in Japan).

Secondly, a group of other Mesoblast programs are included in the first right of refusal, so this is a potential opportunity to fast track other programs.

Thirdly, on the corporate front, Celgene's interest might put some pressure on TEVA (NYSE:TEVA), which has close to a 20% stake in Mesoblast through its acquisition of Cephalon. TEVA also has a major partnership with Mesoblast on chronic heart disease, with phase 3 trials in progress.

For full report see
http://seekingalpha.com/article/306...559813c8533d86478967cc5e7642d50&uprof=45&dr=1